Common interleukin-6promoter variants associate with the more severe forms of distal interphalangeal osteoarthritis
© Kämäräinen et al.; licensee BioMed Central Ltd. 2008
Received: 29 August 2007
Accepted: 08 February 2008
Published: 08 February 2008
The objective of this study was to investigate the relationship of the IL-6 promoter variants G-597A, G-572C and G-174C (rs1800797, rs1800796 and rs1800795, respectively), which have been shown to affect both the transcription and secretion of IL-6, to symptomatic distal interphalangeal (DIP) osteoarthritis (OA).
A total of 535 women aged 45 to 63 years were included. Radiographs of both hands were taken and each DIP joint was evaluated (grade 0 to 4) for the presence of OA. Information on symptoms (pain, tenderness) in each joint was collected by using a self-administered questionnaire. Symptomatic DIP OA was defined by the presence of both radiographic findings of grade 2 or more and symptoms in at least two DIP joints, and symmetrical DIP OA by the presence of radiographic findings of grade 2 or more in at least one symmetrical pair of DIP joints. Common polymorphic loci in the IL-6 gene were amplified and the promoter haplotypes were reconstructed from genotype data with the PHASE program. Logistic regression analysis was used to examine the association between the IL-6 genotypes/diplotypes and the DIP OA outcome.
The G alleles of two promoter single nucleotide polymorphisms (SNPs) G-597A and G-174C were more common among the subjects with symptomatic DIP OA than among those with no disease (P = 0.020 and 0.024, corrected for multiple testing). In addition, the carriage of at least one G allele in these positions increased the risk of disease (P = 0.006 and P = 0.008, respectively). Carrying a haplotype with the G allele in all three promoter SNPs increased the risk of symptomatic DIP OA more than fourfold (odds ratio (OR) 4.45, P = 0.001). Carriage of the G-G diplotype indicated an increased risk of both symmetrical DIP OA (OR 1.52, 95% confidence interval 1.01 to 2.28) and symptomatic DIP OA (OR 3.67, 95% confidence interval 1.50 to 9.00).
The present study showed that the presence of G alleles at common IL-6 polymorphic promoter loci was associated with the more severe DIP OA outcomes, symmetrical and symptomatic.
Osteoarthritis (OA) is a degenerative disorder of the synovial joints causing pain and premature wear and loss of articular cartilage. It is the most common form of arthritic disease, with a strong genetic component [1–3]. The genetic etiology of this complex disease is not well known, although genome-wide linkage analyses and individual gene studies have recently uncovered several genomic areas containing OA-associated variants . The joints of the hand are most commonly affected by OA , and hand OA is highly prevalent particularly among middle-aged women, often being polyarticular . Furthermore, it has been demonstrated recently that the genetic determinants of OA are sex-related and that a joint-specific approach to the genetics of this condition may be more rewarding than a global approach [7, 8]. OA of the distal interphalangeal (DIP) joints is a homogeneous form of OA [9, 10] that has yielded positive results in genome scans, which has previously been unsuccessful in studies that have treated hand OA as a single entity [8, 11].
IL-6 is believed to be one of the major factors in joint destruction, being a pleiotropic pro-inflammatory cytokine that is markedly upregulated at times of tissue inflammation. A significant increase in the level of IL-6 mRNA has been detected in OA-affected cartilage, and the IL-6 levels in the serum and synovial fluid have been reported to be elevated among OA patients . In addition, human recombinant IL-6 has been shown to enhance human recombinant IL-1β-induced proteoglycan degradation and to inhibit chondrocyte proliferation . Known variations within the IL-6 gene have been repeatedly screened in various association studies. According to the reports, a common guanine/cytosine polymorphism at position -174 in the promoter region of the IL-6 gene seems to have a role in a variety of diseases and conditions . This variation regulates the transcription of the IL-6 gene and is associated with plasma levels of IL-6 . The activity of the promoter is also affected by the nearby polymorphic sites at -597 and -572, which seem to control the influence of the polymorphism at position -174 .
Previous studies have suggested that the allelic variations and common haplotypes of the IL-6 gene are related to cartilage-degrading conditions [17, 18]. Functional experiments to study polymorphic effects on the synthesis of IL-6 have shown that its transcription and synthesis are affected by the allelic variations within the gene, although the mechanism and level of the contribution to the actual cartilage-degrading process is still under debate. Another point of view is that IL-6 molecules seem to contribute to the development of the pain sensation and that this effect can be modified by genomic variations, especially in the promoter area of the gene . IL-6 is markedly upregulated in various pathologic situations generally associated with pain and hyperalgesia , and its administration on the skin provokes pain, which increases if it is injected into the cerebrospinal fluid .
This study was undertaken to define how strongly the common genetic variations within the IL-6 gene contribute to the different forms of DIP OA. We report here that the presence of G alleles at common IL-6 polymorphic promoter loci was associated with the more severe forms of DIP OA, symptomatic and symmetrical, in our sample.
Materials and methods
Potential subjects representing two occupational groups with a similar socio-economic status but completely different hand loads, namely dentistry and teaching, were identified through the Finnish Dental Association and the Finnish Teachers' Union. Four hundred and thirty-six women aged 45 to 63 years were randomly selected from each occupational group, using the place of residence as an inclusion criterion (Helsinki or its neighboring cities) for participation in a study concerning work-related factors and individual susceptibility in the etiology of hand osteoarthritis. Of those who received the questionnaires, 295 dentists (67.7%) and 248 teachers (56.9%) participated in a clinical examination. This participation was voluntary, and signed informed consent was obtained from all subjects. The study was approved by the local ethics committee for research in occupational health and safety.
Clinical and radiological assessments
Radiographs of both hands were taken for all the participants, and each DIP joint was evaluated and analyzed by an experienced radiologist who was blinded to all the data regarding the subjects. The presence of hand OA was defined by using a modified Kellgren and Lawrence system  based on the following criteria: grade 0 = no OA (normal finding); grade 1 = suspected OA; grade 2 = mild OA; grade 3 = moderate OA; grade 4 = severe OA. Reference images, as described elsewhere , were used. A second reading was performed independently by the original radiologist and another radiologist for 46 randomly selected subjects. The intra-observer and inter-observer agreements  indicated good reliability for the readings and the grading of OA (from 0.73 to 0.88 and from 0.67 to 0.85, respectively) .
If the subject had at least two DIP joints with radiographic OA of grade 2 to 4, she was classified as having finger DIP OA. Symmetrical DIP OA was defined as a subcategory of DIP OA: OA in at least one symmetrical pair of the DIP joints (if one DIP joint of the hand is affected, the same joint of the opposite hand is also affected).
Information on symptoms (pain, tenderness) in each joint studied was collected by means of the self-administered questionnaire, with the prompt: 'Please point out on the picture below in which finger joint you have felt pain or tenderness during the past 30 days.' The subjects were also asked to mark the intensity of the pain: 0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain. If the subject had both radiographic findings (grade ≥ 2) and symptoms (grade ≥ 1) in at least two corresponding DIP joints, she was classified as having symptomatic DIP OA.
Data regarding individual characteristics were collected by means of a self-administered questionnaire, which included items on anthropometric measures and smoking history. Weight was measured without shoes to an accuracy of 0.1 kg. Body mass index (BMI) (weight (kg) divided by height squared (m2)) was calculated on the basis of the subject's self-reported height and the weight as measured at the clinical examination. BMI was divided into tertiles for logistic regression analysis (low, less than 22.5 kg/m2; medium, 22.5 to 25.5 kg/m2; high, more than 25.5 kg/m2). In terms of their smoking history, the subjects were classified into those who had never smoked and those who had smoked at some time (current or previous smokers).
Genotyping of the IL-6 genomic variants
Three sites with a single nucleotide polymorphism (SNP) at the promoter positions -597, -572 and -174 (G-597A, G-572C and G-174C) were investigated. The corresponding SNP reference numbers are rs1800797, rs1800796 and rs1800795. Genomic DNA was prepared from EDTA-anti-coagulated peripheral blood and used as a template for PCR. The DNA was amplified in a total reaction volume of 23 μl. Genomic DNA (20 ng) was used with 0.25 μM forward and reverse primers, 1.5 μM MgCl2, 0.2 mM dNTPs and 1 U of Ampli Tag Gold polymerase (Applied Biosystems, Foster City, CA, USA). Polymorphic loci were amplified by using previously described primer sequences . PCR cycling conditions were as follows: initial denaturation for 10 minutes at 95°C, 35 cycles at 95°C for 30 s, 60 to 68°C for 30 s and 72°C for 30 s, and a final extension at 72°C for 10 minutes. All the PCR products were sequenced with an ABI PRISM™ 3100 sequencer and BigDye Terminator sequencing kit (Applied Biosystems) to obtain adequate definition of the genotype for all subjects with respect to the different polymorphic loci. The genotyping and recording of the results took place in a double-blinded manner without any personal information on the subjects, for example age or occupation.
For technical reasons, eight blood samples were not genotyped. Of the 535 samples analyzed, we failed to obtain a genotype at promoter position -174 for two subjects and at positions -597 and -572 for three subjects.
Linkage disequilibrium measures between the studied IL-6 promoter single nucleotide polymorphisms
rs1800797 and rs1800796
rs1800797 and rs1800795
rs1800796 and rs1800795
Characteristics of the material
Symptomatic DIP OA
Dentists, n (percentage)
Teachers, n (percentage)
Age, years (mean ± SD)
53.9 ± 5.3
53.6 ± 5.2
57.7 ± 4.2
BMI (mean ± SD)
24.5 ± 3.6
24.4 ± 3.6
25.0 ± 3.3
Never, n (percentage)
Some time, n (percentage)
All the genotype frequencies analyzed were in Hardy–Weinberg equilibrium. No statistically significant differences in the frequencies of the genotypes or carriage rates of the IL-6 polymorphisms were observed between the two occupational groups. Because the two occupational groups proved to be homogeneous with regard to the polymorphisms of interest, they were pooled and the results presented here apply to the whole series, except that the statistical calculations have been adjusted for occupation.
Frequency of the IL-6 (G-174C, G-572C, G-597A) genotypes, by DIP OA status
Symptomatic DIP OA
Condition absent (n = 485)
Condition present (n = 47–48)
G allele carriage
G allele frequency
C allele carriage
C allele frequency
G allele carriage
G allele frequency
Frequency of the IL-6 G-G-G diplotypes, by the DIP OA status (n = 533 to 535)
Odds ratio (95% confidence interval)
Symmetrical DIP OA
Symptomatic DIP OA
Frequency of IL-6 G-G diplotypes (G-597A; G-174C) by DIP OA status (n = 528 to 530)
Odds ratio (95% confidence interval)
Symmetrical DIP OA
Symptomatic DIP OA
The present study showed an association between certain promoter genotypes of IL-6 and the more severe outcomes of DIP OA, namely symmetrical and symptomatic DIP OA. IL-6 is one of the most important mediators of inflammatory reactions in humans. At least 50 SNPs and five common haplotypes have been identified so far in the IL-6 gene, and the genetic variations, especially within the non-coding promoter sequence, have been shown to have a powerful influence on the expression of the gene [26–28]. Pain and inflammation symptoms are known to be related to IL-6, and it was recently reported by Oen and coworkers that the promoter genotype -174GG has a positive correlation with pain in juvenile rheumatoid arthritis .
It has been reported previously that IL-6 production ex vivo is greater in individuals who are homozygous for the haplotype containing G at -597 and -174 . This is interesting in the light of the fact that both of these G alleles substantially increased the risk of symptomatic OA in our material. Individually, the G allele of the G-174C variation has repeatedly been shown to associate with increased expression and plasma levels of IL-6 [17, 30], and the same polymorphism has recently been directly linked to hip OA, because the CC genotype was significantly higher in the control population . The three promoter variations G-597A, G-572C and G-174C have been shown to influence IL-6 transcription through a complex interaction determined by the haplotype, and the G alleles at these loci have been found to associate with increased transcription of IL-6 . Our results strongly support this finding, because the G-G-G haplotype was clearly overrepresented among those with a symptomatic disease in our sample.
OA can be defined by symptoms or pathology (radiographic features). Although osteoarthritis is regarded as a likely origin of joint pain , the association between radiographic evidence of OA and symptoms in the general population seems to be rather poor, as many persons with radiographic OA do not have any symptoms, and vice versa . The American College of Rheumatology criteria for the classification of OA identify cases of persistent pain (most days for at least 1 month). The proportion of radiographic OA that is symptomatic has been estimated to be between 20% and 40%, and most persons with radiographic OA do not have persistent symptoms . Although the American College of Rheumatology criteria are the most frequently used definition of symptomatic hand OA for clinical studies, their limitations for epidemiological studies have been recognized . The available evidence suggests that radiography is better than clinical examination for defining hand OA in epidemiological studies, and that it is possible to identify persons with clinically significant OA by combining a radiographic criterion with self-reported symptoms . It has recently been shown in this same population that the severity of finger joint pain is clearly dependent on the severity of radiographic OA .
We sought here to examine more severe cases of OA, those that are more likely to have a genetic component. All the subjects were uniformly assessed for the presence of radiographic DIP OA and the joint-specific occurrence of symptoms. The outcome of symptomatic DIP OA in at least two joints was chosen in view of its assumed clinical relevance and its specificity in terms of joint location.
Although our results are supported by the findings of several functional studies of IL-6 gene transcription [15, 16, 28, 29, 34], there are also negative results concerning the contribution of promoter variability . One explanation for this could be the effect of aging, which may overwhelm the genetic effect on the IL-6 levels. There is substantial evidence that the increase in IL-6 serum levels with age results in part from the loss of sex steroids such as estrogen, testosterone and dehydroepiandrosterone [36, 37], which have an important role in blocking transcription of the IL-6 gene, so that their loss at menopause may have a more conspicuous role than the genotype.
Our findings do not suggest an association between the development of asymptomatic DIP OA and the IL-6 gene, because the risk of radiographic OA was not affected by the IL-6 genotype. The number of individuals with radiographic DIP OA having symptoms turned out to be relatively low compared with the total number of subjects, which reduced the power of the results, so that replication with a larger sample would be beneficial. In addition, a cross-sectional study setting may result in difficulties in accurately estimating the true risk of DIP OA associated with IL-6 promoter variants. The experiencing and evaluation of symptoms, particularly pain, are always individual, purely subjective and likely to fluctuate with time. It should be noted that a self-administered questionnaire cannot preclude other causes of joint pain in addition to DIP OA. In contrast, asymptomatic periods of variable duration are typical of osteoarthritis, and the present subjects were prompted to report symptoms that had occurred within the previous 30 days. It is therefore possible that the number of symptomatic subjects in our sample is lower than it should be, as a result of the exclusion of those who were going through an asymptomatic period at the time of answering the questionnaire. The association between IL-6 and symptomatic DIP OA may therefore be even stronger than that reported here. A strict time scale for the occurrence of reported symptoms combined with the radiological analysis should reduce the amount of bias caused by temporary, indistinct joint symptoms not caused by DIP OA. In general, this work underlines the importance of a homogeneous study population with a specific outcome formulation, to avoid allowing the modest genetic contribution to be overwhelmed by the clinical diversity of the subjects.
Our findings lend support to the notion of an association between promoter variations in the IL-6 gene and symptomatic and symmetrical DIP OA, outcomes that can be presumed to be of high clinical relevance. It may be possible in future to make therapeutic use of the knowledge of IL-6 and its significance as a cause of inflammation and pain, in treating symptoms of arthritis. Specific IL-6 receptor antagonists inhibiting the inflammation cascade within the articular cartilage are a relevant option when designing new therapeutic interventions for this disease.
= body mass index
= confidence interval
= distal interphalangeal
= linkage disequilibrium
= odds ratio
= single nucleotide polymorphism.
The authors wish to thank all the participants in this study. Ms Aira Harju at the Department of Medical Biochemistry and Molecular Biology, University of Oulu, is gratefully acknowledged for technical assistance. This work was financially supported by the Finnish Work Environment Fund and the Academy of Finland.
- Spector TD, Cicuttini F, Baker J, Loughlin J, Hart D: Genetic influences on osteoarthritis in women: a twin study. BMJ. 1996, 312: 940-943.PubMed CentralView ArticlePubMedGoogle Scholar
- Spector TD, MacGregor AJ: Risk factors for osteoarthritis: genetics. Osteoarthritis Cartilage. 2004, 12: 39-44. 10.1016/j.joca.2003.09.005.View ArticleGoogle Scholar
- Spencer JM, Loughlin J, Clipsham K, Carr AJ: Genetic background increases the risk of hip osteoarthritis. Clin Orthop Relat Res. 2005, 431: 134-137. 10.1097/01.blo.0000149242.85548.00.View ArticlePubMedGoogle Scholar
- Loughlin J: The genetic epidemiology of human primary osteoarthritis: current status. Expert Rev Mol Med. 2005, 7: 1-12. 10.1017/S1462399405009257.View ArticlePubMedGoogle Scholar
- Felson DT: Epidemiology of hip and knee osteoarthritis. Epidemiol Rev. 1988, 10: 1-28.PubMedGoogle Scholar
- Solovieva S, Vehmas T, Riihimäki H, Luoma K, Leino-Arjas P: Hand use and patterns of joint involvement in osteoarthritis. A comparison of female dentists and teachers. Rheumatology. 2005, 44: 521-528. 10.1093/rheumatology/keh534.View ArticlePubMedGoogle Scholar
- Kaprio J, Kujala UM, Peltonen L, Koskenvuo M: Genetic liability to osteoarthritis may be greater in women than men. BMJ. 1996, 313: 232-PubMed CentralView ArticlePubMedGoogle Scholar
- Hunter DJ, Demissie S, Cupples LA, Aliabadi P, Felson DT: A genome scan for joint-specific hand osteoarthritis susceptibility: The Framingham Study. Arthritis Rheum. 2004, 50: 2489-2496. 10.1002/art.20445.View ArticlePubMedGoogle Scholar
- Felson DT, Lawrence RC, Dieppe PA, Hirsch R, Helmick CG, Jordan JM, Kington RS, Lane NE, Nevitt Mc, Zhang Y, Sowers M, McAlindon T, Spector TD, Poole AR, Yanovski SZ, Ateshian G, Sharma L, Buckwalter JA, Brandt KD, Fries JF: Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med. 2000, 133: 635-646.View ArticlePubMedGoogle Scholar
- Jones G, Cooley HM, Stankovich JM: A cross sectional study of the association between sex, smoking, and other lifestyle factors and osteoarthritis of the hand. J Rheumatol. 2002, 29: 1719-1724.PubMedGoogle Scholar
- Leppävuori J, Kujala U, Kinnunen J, Kaprio J, Nissilä M, Heliövaara M, Klinger M, Partanen J, Terwilliger JD, Peltonen L: Genome scan for predisposing loci for distal interphalangeal joint osteoarthritis: evidence for a locus on 2q. Am J Hum Genet. 1999, 65: 1060-1067. 10.1086/302569.PubMed CentralView ArticlePubMedGoogle Scholar
- Kaneko S, Satoh T, Chiba J, Ju C, Inoue K, Kagawa J: Interleukin-6 and interleukin-8 levels in serum and synovial fluid of patients with osteoarthritis. Cytokines Cell Mol Ther. 2000, 6: 71-79. 10.1080/13684730050515796.View ArticlePubMedGoogle Scholar
- Jikko A, Wakisaka T, Iwamoto M, Hiranuma H, Kato Y, Maeda T, Fujishita M, Fuchihata H: Effects of interleukin-6 on proliferation and proteoglycan metabolism in articular chondrocyte cultures. Cell Biol Int. 1998, 22: 615-621. 10.1006/cbir.1998.0304.View ArticlePubMedGoogle Scholar
- Papassotiropoulos A, Hock C, Nitsch RM: Genetics of interleukin 6: implications for Alzheimer's disease. Neurobiol Aging. 2001, 22: 863-871. 10.1016/S0197-4580(01)00294-9.View ArticlePubMedGoogle Scholar
- Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P: The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest. 1998, 102: 1369-1376. 10.1172/JCI2629.PubMed CentralView ArticlePubMedGoogle Scholar
- Terry CF, Loukaci V, Green FR: Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem. 2000, 275: 18138-18144. 10.1074/jbc.M000379200.View ArticlePubMedGoogle Scholar
- Noponen-Hietala N, Virtanen I, Karttunen R, Schwenke S, Jakkula E, Li H, Merikivi R, Barral S, Ott J, Karppinen J, Ala-Kokko L: Genetic variations in IL6 associate with intervertebral disc disease characterized by sciatica. Pain. 2005, 114: 186-194. 10.1016/j.pain.2004.12.015.View ArticlePubMedGoogle Scholar
- Pola E, Papaleo P, Pola R, Gaetani E, Tamburelli FC, Aulisa L, Logroscino CA: Interleukin-6 gene polymorphism and risk of osteoarthritis of the hip: a case-control study. Osteoarthritis Cartilage. 2005, 13: 1025-1028. 10.1016/j.joca.2005.07.011.View ArticlePubMedGoogle Scholar
- Oen K, Malleson PN, Cabral DA, Rosenberg AM, Petty RF, Nickerson P, Reed M: Cytokine genotypes correlate with pain and radiologically defined joint damage in patients with juvenile rheumatoid arthritis. Rheumatology. 2005, 44: 1115-1121. 10.1093/rheumatology/keh689.View ArticlePubMedGoogle Scholar
- Sommer C, Kress M: Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci Lett. 2004, 361: 184-187. 10.1016/j.neulet.2003.12.007.View ArticlePubMedGoogle Scholar
- De Jongh RF, Vissers KC, Meert TF, Booij LH, De Deyne CS, Heylen RJ: The role of interleukin-6 in nociception and pain. Anesth Analg. 2003, 96: 1096-1103. 10.1213/01.ANE.0000055362.56604.78.View ArticlePubMedGoogle Scholar
- Kellgren JH, Lawrence JS: Radiologic assessment of osteoarthritis. Ann Rheum Dis. 1957, 16: 494-502.PubMed CentralView ArticlePubMedGoogle Scholar
- Cohen J: Weighted kappa. Nominal scale agreement with provision for scaled disagreement or partial credit. Psychol Bull. 1968, 70: 213-220. 10.1037/h0026256.View ArticlePubMedGoogle Scholar
- Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005, 21: 263-265. 10.1093/bioinformatics/bth457.View ArticlePubMedGoogle Scholar
- Stephens M, Smith NJ, Donnelly P: A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001, 68: 978-989. 10.1086/319501.PubMed CentralView ArticlePubMedGoogle Scholar
- Osiri M, McNicholl J, Moreland LW, Bridges SL: A novel single nucleotide polymorphism and five probable haplotypes in the 5' flanking region of the IL-6 gene in African-Americans. Genes Immun. 1999, 1: 166-167. 10.1038/sj.gene.6363652.View ArticlePubMedGoogle Scholar
- Jordanies N, Eskdale J, Stuart R, Gallagher G: Allele associations reveal four prominent haplotypes at the human interleukin-6 (IL-6) locus. Genes Immun. 2000, 1: 451-455. 10.1038/sj.gene.6363699.View ArticleGoogle Scholar
- Ota N, Nakajima T, Nakazawa I, Suzuki T, Hosoi T, Orimo H, Inoue S, Shirai Y, Emi M: A nucleotide variant in the promoter region of the interleukin-6 gene associated with decreased bone mineral density. J Hum Genet. 2001, 46: 267-272. 10.1007/s100380170077.View ArticlePubMedGoogle Scholar
- Rivera-Chavez FA, Peters-Hybki DL, Barber RC, O'Keefe GE: Interleukin-6 promoter haplotypes and interleukin-6 cytokine responses. Shock. 2003, 20: 218-223. 10.1097/00024382-200309000-00004.PubMed CentralView ArticlePubMedGoogle Scholar
- Bennermo M, Held C, Stemme S, Ericsson CG, Silveira A, Green F, Tornvall P: Genetic predisposition of the interleukin-6 response to inflammation: implications for a variety of major diseases?. Clin Chem. 2004, 50: 2136-2140. 10.1373/clinchem.2004.037531.View ArticlePubMedGoogle Scholar
- Dieppe PA, Lohmander LS: Pathogenesis and management of pain in osteoarthritis. Lancet. 2005, 365: 965-973. 10.1016/S0140-6736(05)71086-2.View ArticlePubMedGoogle Scholar
- Hart DJ, Spector TD: Definition and epidemiology of osteoarthritis of the hand: a review. Osteoarthritis Cartilage. 2000, S2-S7. Suppl 8A
- Ding H, Solovieva S, Vehmas T, Riihimäki H, Leino-Arjas P: Finger joint pain in relation to radiographic osteoarthritis and joint location – a study of middle-aged female dentists and teachers. Reumatology. 2007, 46: 1502-1505. 10.1093/rheumatology/kem185.View ArticleGoogle Scholar
- Hulkkonen J, Pertovaara M, Antonen J, Pasternack A, Hurme M: Elevated interleukin-6 plasma levels are regulated by the promoter region polymorphism of the IL6 gene in primary Sjogren's syndrome and correlate with the clinical manifestations of the disease. Rheumatology. 2001, 40: 656-661. 10.1093/rheumatology/40.6.656.View ArticlePubMedGoogle Scholar
- Walston J, Arking DE, Fallin D, Li T, Beamer B, Xue Q, Ferrucci L, Fried LP, Chakravarti A: IL-6 gene variation is not associated with increased serum levels of IL-6, muscle, weakness, or frailty in older women. Exp Gerontol. 2005, 40: 344-352. 10.1016/j.exger.2005.01.012.View ArticlePubMedGoogle Scholar
- Ershler WB, Keller ET: Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med. 2000, 51: 245-270. 10.1146/annurev.med.51.1.245.View ArticlePubMedGoogle Scholar
- Pfeilschifter J, Koditz R, Pfohl M, Schatz H: Changes in proinflammatory cytokine activity after menopause. Endocr Rev. 2002, 23: 90-119. 10.1210/er.23.1.90.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.